AbbVie Inc. is 7.0x more valuable than REGENERON PHARMACEUTICALS, INC. by market capitalization ($397.44 B vs $56.80 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | REGN | ABBV |
|---|---|---|
| Market cap | $56.80 B | $397.44 B |
| US-listed rank | #291 | #28 |
| Revenue (latest FY) | $14.34B | $61.16B |
| Net income (latest FY) | $4.50B | $4.23B |
| Net margin | 31.4% | 6.9% |
| P/E (trailing FY) | 12.6 | 94.0 |
| SEC filings | 985 | 1,008 |
AbbVie Inc. is 7.0x more valuable than REGENERON PHARMACEUTICALS, INC. by market capitalization ($397.44 B vs $56.80 B).
In their latest fiscal years, REGENERON PHARMACEUTICALS, INC. reported $14.34B in revenue while AbbVie Inc. reported $61.16B.
Full pages: REGENERON PHARMACEUTICALS, INC. and AbbVie Inc., or browse the full rankings.